Zyus adds two clinical sites to phase 2a Utopia-1 trial

Executive Summary

• Zyus Life Sciences activated two additional Canadian clinical sites—CancerCare Manitoba and the Research Institute of the McGill University Health Centre (CHUM)—expanding its Phase 2A Utopia‑1 cancer pain trial to three sites.
• The expansion broadens participant diversity and is expected to accelerate patient enrollment for the Trichomylin soft‑gel capsule program.
• President & CEO Brent Zettl highlighted that the added sites move the company closer to generating preliminary efficacy and safety data needed for later‑stage trials.

Key Details

• New Sites Added: CancerCare Manitoba (CCMB) and Research Institute of the McGill University Health Centre / Centre Hospitalier de l'Université de Montréal (CHUM).
• Trial Scope: Phase 2A Utopia‑1 (Unique Treatment of Oncology Pain in Advanced Cancer) now has three active sites across Canada.
• Study Design: Single‑arm, proof‑of‑concept evaluating safety and preliminary analgesic efficacy of Trichomylin soft‑gel capsules in patients with advanced cancer experiencing moderate to severe pain.
• Strategic Impact: Expanded site network expected to increase enrollment speed and enhance demographic diversity of trial participants.
• Future Milestones: Generation of preliminary efficacy and safety data to support progression of Trichomylin into later‑stage clinical trials.

Notable Quotes

“Expanding the Utopia‑1 trial to three clinical sites marks a meaningful step forward in our mission to deliver safer, scientifically validated alternatives that have the potential to improve patient outcomes,” – Brent Zettl, President & CEO, Zyus Life Sciences.

All boilerplate and safe‑harbor language omitted for brevity.